Key result
Bevacizumab increases fatal adverse event risk ~29% vs. chemotherapy alone in cancer patients.
Why the study?
Does bevacizumab added to chemotherapy increase fatal adverse events in cancer patients?
Population
Cancer patients from 34 randomized controlled trials
Comparison
Bevacizumab added to chemotherapy vs Chemotherapy alone
Design
Meta-analysis
Authors
Loading...
Bevacizumab plus chemotherapy warrants caution due to elevated fatal event risk; confirms this hazard across aggregated randomized trials.
Meta-Analysis (n=25,424)
Does bevacizumab added to chemotherapy increase fatal adverse events in cancer patients?
Effect estimate: RR 1.29 (95% CI 1.05-1.57)
Absolute Event Rate: 1.48% vs 0.93%
p-value: p=0.01
The addition of bevacizumab to chemotherapy is associated with a significantly increased risk of fatal adverse events in cancer patients, particularly with certain tumor types and concomitant agents.
Huang et al. (2014) conducted a meta-analysis in Cancer (n=25,424). Bevacizumab vs. Non-bevacizumab containing therapy (chemotherapy alone) was evaluated on Fatal adverse events (FAEs) (RR 1.29, 95% CI 1.05-1.57, p=0.01). Bevacizumab therapy significantly increased the risk of fatal adverse events (RR 1.29) compared to chemotherapy alone in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: